Annals of Hematology

, Volume 89, Issue 8, pp 803–811 | Cite as

Consensus guidelines for the optimal management of adverse events in newly diagnosed, transplant-ineligible patients receiving melphalan and prednisone in combination with thalidomide (MPT) for the treatment of multiple myeloma

  • A. Palumbo
  • F. Davies
  • M. Kropff
  • J. Bladé
  • M. Delforge
  • F. Leal da Costa
  • R. Garcia Sanz
  • S. Schey
  • T. Facon
  • G. Morgan
  • P. Moreau
Original Article

Abstract

Thalidomide has received approval from the European Agency for the Evaluation of Medicinal Products for the treatment of newly diagnosed multiple myeloma (MM) patients older than 65 years or ineligible for transplant. The results of five phase III trials assessing thalidomide in combination with melphalan and prednisone (MPT) have demonstrated significantly improved response rates compared with melphalan and prednisone (MP) alone. Additionally, two of these studies showed that survival was extended by approximately 18 months in patients treated with MPT compared with MP alone. Thalidomide, in combination with MP, is associated with adverse events (AEs) including peripheral neuropathy and venous thromboembolism. In order to optimize the efficacy of MPT, a good awareness of these AEs is imperative. This manuscript outlines both evidence- and consensus-based recommendations discussed by a panel of experts, to provide a practical guide for physicians addressing the effective management of newly diagnosed, transplant-ineligible MM patients receiving thalidomide therapy.

Keywords

Myeloma MM Thalidomide Treatment guidelines 

Notes

Acknowledgments

Research support was provided by Celgene Ltd. Editorial support was provided by Dr. Marion James from ScopeMedical Ltd, funded by Celgene Ltd.

References

  1. 1.
    Smith A, Wisloff F, Samson D (2005) Guidelines on the diagnosis and management of multiple myeloma 2005. Br J Haematol 132:410–451CrossRefGoogle Scholar
  2. 2.
    Anderson KC. NCCN Clinical Practice Guidelines 2008Google Scholar
  3. 3.
    Myeloma Trialists' Collaborative Group (1998) Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. J Clin Oncol 16:3832–3842Google Scholar
  4. 4.
    Singhal S, Meta J, Disakan R et al (1999) Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 341:1565–1571CrossRefPubMedGoogle Scholar
  5. 5.
    Barlogie B, Disikan R, Eddlemon P et al (2001) Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood 98:492–494CrossRefPubMedGoogle Scholar
  6. 6.
    van Rhee F, Dhodapkar M, Shaughnessy JD Jr et al (2008) First thalidomide clinical trial in multiple myeloma: a decade later. Blood 112:1035–1038CrossRefPubMedGoogle Scholar
  7. 7.
    Palumbo A, Bringhen S, Caravita T et al (2006) Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 367:825–831CrossRefPubMedGoogle Scholar
  8. 8.
    Facon T, Mary JY, Hulin C et al (2007) Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet 370:1209–1218CrossRefPubMedGoogle Scholar
  9. 9.
    Hulin C, Virion J, Leleu X et al (2009) Efficacy of melphalan-prednisone-thalidomide (MP-T) to melphalan-prednisone (MP) in patients 75 years of age or older with untreated multiple myeloma (MM). Preliminary results of the randomized, double-blind, placebo controlled IFM 01-01 trial. J Clin Oncol 27:3664–3670CrossRefPubMedGoogle Scholar
  10. 10.
    Waage A, Gimsing P, Juliusson G et al (2007) Melphalan-prednisone-thalidomide to newly diagnosed patients with multiple myeloma: a placebo controlled randomised phase 3 trial. ASH Annual Meeting abstracts Blood 110:78Google Scholar
  11. 11.
    Wijermans P (2009) Melphalan + prednisone versus melphalan + prednisone + thalidomide in induction therapy for multiple myeloma in elderly patients: final analysis of the Dutch Cooperative Group HOVON 49 study. Blood 112. Abstract 649Google Scholar
  12. 12.
    Palumbo A, Bringhen S, Liberati AM et al (2008) Oral melphalan, prednisone and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial. Blood 112:3107–3114CrossRefPubMedGoogle Scholar
  13. 13.
    Dispenzieri A, Rajkumar SV, Gertz MA et al (2007) Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement. Mayo Clin Proc 82:323–341CrossRefPubMedGoogle Scholar
  14. 14.
    Thalidomide Celgene SmPC (2008)Google Scholar
  15. 15.
    Palumbo A, Falco P, Corradini P et al (2007) Melphalan, prednisone and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA—Italian multiple myeloma network. J Clin Oncol 25:4459–4465CrossRefPubMedGoogle Scholar
  16. 16.
    Palumbo A, Rajkumar SV, Dimopoulos MA et al (2008) Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 22:414–423CrossRefPubMedGoogle Scholar
  17. 17.
    Silverstein MD, Heit JA, Mohr DN et al (1998) Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med 158:585–593CrossRefPubMedGoogle Scholar
  18. 18.
    Heit JA, Silverstein MD, Mohr DN (1999) Predictors of survival after deep vein thrombosis and pulmonary embolism: a population-based, cohort study. Arch Intern Med 159:445–453CrossRefPubMedGoogle Scholar
  19. 19.
    Sallah S, Wan JY, Nguyen NP (2002) Venous thrombosis in patients with solid tumors: determination of frequency and characteristics. Thromb Haemost 87:575–579PubMedGoogle Scholar
  20. 20.
    Blom JW, Doggen CJ, Osanto S et al (2005) Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 293:715–722CrossRefPubMedGoogle Scholar
  21. 21.
    Boersma RS, Jie KS, Verbon A et al (2008) Thrombotic and infectious complications of central venous catheters in patients with hematological malignancies. Ann Oncol 19:433–432CrossRefPubMedGoogle Scholar
  22. 22.
    El Accaoui RN, Shamseddeen WA, Taher AT (2007) Thalidomide and thrombosis. A meta-analysis. Thromb Haemost 97:1031–1036PubMedGoogle Scholar
  23. 23.
    Zangari M, Siegel E, Barlogie B et al (2002) Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy. Blood 100:1168–1171CrossRefPubMedGoogle Scholar
  24. 24.
    Zangari M, Barlogie B, Thertulien R et al (2003) Thalidomide and deep vein thrombosis in multiple myeloma: risk factors and effect on survival. Clin Lymphoma 4:32–35CrossRefPubMedGoogle Scholar
  25. 25.
    Schutt P, Ebeling P, Buttkereit U et al (2005) Thalidomide in combination with vincristine, epirubicin and dexamethasone (VED) for previously untreated patients with multiple myeloma. Eur J Haematol 74:40–46CrossRefPubMedGoogle Scholar
  26. 26.
    Johnson DC, Corthals S, Ramos C et al (2008) Genetic associations with thalidomide mediated venous thrombotic events in myeloma using targeted genotyping. Blood 112:4924–4934CrossRefPubMedGoogle Scholar
  27. 27.
    Palumbo A, Cavo M, Bringhen S et al (2007) A prospective, randomized, phase III study of enoxaparin versus aspirin versus low-fixed-dose of warfarin in newly diagnosed myeloma patients treated with thalidomide-containing regimens. Blood 110. Abstract 310Google Scholar
  28. 28.
    Costa G, Engle RL Jr, Schilling A et al (1973) Melphalan and prednisone: an effective combination for the treatment of multiple myeloma. Am J Med 54:589–599CrossRefGoogle Scholar
  29. 29.
    Plasmati R, Pastorelli F, Cavo M et al (2007) Neuropathy in multiple myeloma treated with thalidomide: a prospective study. Neurology 69:573–581CrossRefPubMedGoogle Scholar
  30. 30.
    San Miguel J, Blade J, Boccadoro M et al (2006) A practical update on the use of bortezomib in the management of multiple myeloma. Oncologist 11:51–61CrossRefPubMedGoogle Scholar
  31. 31.
    Richardson PG, Briemberg H, Jagannath S et al (2006) Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 24:3113–3120CrossRefPubMedGoogle Scholar
  32. 32.
    Ghobrial IM, Rajkumar SV (2003) Management of thalidomide toxicity. J Support Oncol 1:194–205PubMedGoogle Scholar
  33. 33.
    Cavaletti G, Beronio A, Reni L et al (2004) Thalidomide sensory neurotoxicity: a clinical and neurophysiologic study. Neurology 62:2291–2293PubMedGoogle Scholar
  34. 34.
    Mileshkin L, Stark R, Day B et al (2006) Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring. J Clin Oncol 24:4507–4514CrossRefPubMedGoogle Scholar
  35. 35.
    Kaur A, Yu SS, Lee AJ (2003) Thalidomide-induced sinus bradycardia. Ann Pharmacother 37:1040–1043CrossRefPubMedGoogle Scholar
  36. 36.
    Fahdi IE, Gaddam V, Saucedo JF et al (2004) Bradycardia during therapy for multiple myeloma with thalidomide. Am J Cardiol 93:1052–1055CrossRefPubMedGoogle Scholar
  37. 37.
    Bladé J, Esteve J, Rosiñol L et al (2001) Thalidomide in refractory and relapsing multiple myeloma. Semin Oncol 28:588–592CrossRefPubMedGoogle Scholar
  38. 38.
    García-Sanz R, González-Porras JR, Hernández JM et al (2004) The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed/refractory multiple myeloma. Leukemia 18:856–863CrossRefPubMedGoogle Scholar
  39. 39.
    Mateos MV, Oriol A, Martínez J et al (2008) Bortezomib (Velcade)-melphalan-prednisone (VMP) versus velcade-thalidomide-prednisone (VTP) in elderly untreated multiple myeloma patients: which is the best partner for velcade: an alkylating or an immunomodulator agent? Blood 112. Abstract 651Google Scholar
  40. 40.
    Hall VC, El-Azhary RA, Bouwhuis S et al (2003) Dermatologic side effects of thalidomide in patients with multiple myeloma. J Am Acad Dermatol 48:548–552CrossRefPubMedGoogle Scholar
  41. 41.
    Horowitz SB, Stirling AL (1999) Thalidomide-induced toxic epidermal necrolysis. Pharmacotherapy 19:1177–1180CrossRefPubMedGoogle Scholar
  42. 42.
    Rajkumar SV, Gertz MA, Witzig TE (2000) Life-threatening toxic epidermal necrolysis with thalidomide therapy for myeloma. N Engl J Med 343:972–973CrossRefPubMedGoogle Scholar
  43. 43.
    Nijsten T, Meuleman L, Schroyens W et al (2002) Thalidomide-induced morbilliform rash: diagnosis and continuation of therapy, premedicated with methylprednisolone. Dermatology 204:365–367CrossRefPubMedGoogle Scholar
  44. 44.
    Amin N, Brancaccio R, Cohen D (2006) Cutaneous reactions to injectable corticosteroids. Dermatitis 17:143–146PubMedGoogle Scholar
  45. 45.
    Dimopoulos MA, Kastritis E, Rosinol L et al (2008) Pathogenesis and treatment of renal failure in multiple myeloma. Leukemia 22:1485–1493CrossRefPubMedGoogle Scholar
  46. 46.
    Eriksson T, Höglund P, Turesson I et al (2003) Pharmacokinetics of thalidomide in patients with impaired renal function and while on and off dialysis. J Pharm Pharmacol 55:1701–1706CrossRefPubMedGoogle Scholar
  47. 47.
    Chen N, Lau H, Kong L et al (2007) Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis. J Clin Pharmacol 47:1466–1475CrossRefPubMedGoogle Scholar
  48. 48.
    Pineda-Roma M, Tricot G (2007) High-dose therapy in patients with plasma cell dyscrasias and renal dysfunction. Contrib Nephrol 153:182–194CrossRefGoogle Scholar
  49. 49.
    Palumbo A, Boccadoro M (2007) A new standard of care for elderly patients with myeloma. Lancet 370:1191–1192CrossRefPubMedGoogle Scholar
  50. 50.
    San Miguel JF, Schlag R, Khuageva NK et al (2008) Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. New Engl J Med 359:906–917CrossRefPubMedGoogle Scholar
  51. 51.
    Wang M, Dimopoulos M, Chen C et al (2008) Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure. Blood 112:4445–4451CrossRefPubMedGoogle Scholar
  52. 52.
    Sonneveld P, Hajek R, Nagler A et al (2008) Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy. Cancer 112:1529–1537CrossRefPubMedGoogle Scholar
  53. 53.
    Sidra G, Williams CD, Russell NH et al (2006) Combination chemotherapy with cyclophosphamide, thalidomide and dexamethasone for patients with refractory, newly diagnosed or relapsed myeloma. Haematologica 91:862–863PubMedGoogle Scholar
  54. 54.
    Fonseca R, Stewart AK (2007) Targeted therapeutics for multiple myeloma: the arrival of a risk-stratified approach. Mol Cancer Ther 6:802–810CrossRefPubMedGoogle Scholar
  55. 55.
    Barlogie B, Pineda-Roman M, van Rhee F et al (2008) Thalidomide arm of total therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities. Blood 112:3115–3121CrossRefPubMedGoogle Scholar
  56. 56.
    Dimopoulos MA, Eleutherakis-Papaiakovou V (2004) Adverse effects of thalidomide administration in patients with neoplastic diseases. Am J Med 117:508–515CrossRefPubMedGoogle Scholar
  57. 57.
    Murphy PT, O’Donnell JR (2006) Thalidomide induced impotence in male hematology patients: a common but ignored complication? Haematologica 92:1440CrossRefGoogle Scholar
  58. 58.
    Rajkumar SV, Gertz MA, Lacy MQ et al (2003) Thalidomide as initial therapy for early-stage myeloma. Leukemia 17:775–779CrossRefPubMedGoogle Scholar
  59. 59.
    Weber D, Rankin K, Gavino M et al (2003) Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 21:16–19CrossRefPubMedGoogle Scholar
  60. 60.
    Rajkumar SV, Blood E, Vesole D et al (2006) Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 24:431–436CrossRefPubMedGoogle Scholar
  61. 61.
    Cavo M, Zamagni E, Tosi P et al (2004) First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma. Haematologica 89:826–831PubMedGoogle Scholar
  62. 62.
    Rajkumar SV, Hayman S, Gertz M et al (2002) Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol 20:4319–4323CrossRefPubMedGoogle Scholar
  63. 63.
    Osman K, Comenzo R, Rajkumar SV (2001) Deep venous thrombosis and thalidomide therapy for multiple myeloma. N Engl J Med 344:1951–1952CrossRefPubMedGoogle Scholar
  64. 64.
    Zervas K, Dimopoulos MA, Hatzicharissi E et al (2004) Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): a phase II multicenter study. Ann Oncol 15:134–138CrossRefPubMedGoogle Scholar
  65. 65.
    Wu P, Davies FE, Horton C et al (2006) The combination of cyclophosphomide, thalidomide and dexamethasone is an effective alternative to cyclophosphamide–vincristine–doxorubicin–methylprednisolone as induction chemotherapy prior to autologous transplantation for multiple myeloma: a case-matched analysis. Leuk Lymphoma 47:2335–2338CrossRefPubMedGoogle Scholar
  66. 66.
    Barlogie B, Tricot G, Anaissie E et al (2006) Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med 354:1021–1030CrossRefPubMedGoogle Scholar
  67. 67.
    Neben K, Moehler T, Benner A et al (2002) Dose-dependent effect of thalidomide on overall survival in relapsed multiple myeloma. Clin Cancer Res 8:3377–3382PubMedGoogle Scholar
  68. 68.
    Schey SA, Cavenagh J, Johnson R et al (2003) An UK myeloma forum phase II study of thalidomide; long term follow-up and recommendations for treatment. Leuk Res 27:909–914CrossRefPubMedGoogle Scholar
  69. 69.
    Anagnostopoulos A, Weber D, Rankin K et al (2003) Thalidomide and dexamethasone for resistant multiple myeloma. Br J Haematol 121:768–771CrossRefPubMedGoogle Scholar
  70. 70.
    Palumbo A, Bertola A, Falco P et al (2004) Efficacy of low-dose thalidomide and dexamethasone as first salvage regimen in multiple myeloma. Hematol J 5:318–324CrossRefPubMedGoogle Scholar
  71. 71.
    Baz R, Li L, Kottke-Marchant K et al (2005) The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma. Mayo Clin Proc 80:1568–1574CrossRefPubMedGoogle Scholar
  72. 72.
    Dimopoulos MA, Hamilos G, Zomas A et al (2004) Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for previously treated patients with multiple myeloma. Hematol J 5:112–117CrossRefPubMedGoogle Scholar
  73. 73.
    Kropff MH, Lang N, Bisping G et al (2003) Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma. Br J Haematol 122:607–616CrossRefPubMedGoogle Scholar
  74. 74.
    Suvannasankha A, Fausel C, Juliar BE et al (2007) Final report of toxicity and efficacy of a phase II study of oral cyclophosphamide, thalidomide, and prednisone for patients with relapsed or refractory multiple myeloma: a Hoosier Oncology Group Trial, HEM01-21. Oncologist 12:99–106CrossRefPubMedGoogle Scholar
  75. 75.
    Lee CK, Barlogie B, Munshi N et al (2003) DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma. J Clin Oncol 21:2732–2739CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • A. Palumbo
    • 1
  • F. Davies
    • 2
  • M. Kropff
    • 3
  • J. Bladé
    • 4
  • M. Delforge
    • 5
  • F. Leal da Costa
    • 6
  • R. Garcia Sanz
    • 7
  • S. Schey
    • 8
  • T. Facon
    • 9
  • G. Morgan
    • 2
  • P. Moreau
    • 10
  1. 1.University of TorinoTurinItaly
  2. 2.Institute of Cancer Research and Royal Marsden HospitalSuttonUK
  3. 3.University Clinic of MuensterMuensterGermany
  4. 4.Hospital Clinic, IDIBAPSInstitut Clinic de Malaties Hematologiques i OncologiquesBarcelonaSpain
  5. 5.Catholic UniversityLeuvenBelgium
  6. 6.Portuguese Institute of OncologyLisbonPortugal
  7. 7.Hospital Universitario de SalamancaSalamancaSpain
  8. 8.King’s College HospitalLondonUK
  9. 9.Lille University HospitalLilleFrance
  10. 10.University of NantesNantesFrance

Personalised recommendations